Identification of Risk Factors for COVID‐19 Hospitalization in Patients With Anti‐Rheumatic Drugs: Results From a Multicenter Nested Case Control Study
Open Access
- 23 February 2022
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 111 (5) , 1061-1065
Abstract
Patients with inflammatory rheumatic diseases (IRDs) do not have an increased risk for coronavirus disease 2019 (COVID‐19) compared with the general population. However, it remains uncertain whether subgroups of patients with IRD using different immunosuppressive antirheumatic drugs carry a higher risk for severe COVID‐19 compared with other patients with IRD. The aim of this study is to identify risk factors for severe COVID‐19, requiring hospitalization in patients with IRD. This is a multicenter nested case control study conducted in the Netherlands. Cases are hospital known patients with IRD requiring hospitalization for COVID‐19 between March 1, 2020, and May 31, 2020. Controls are hospital known patients with IRD not requiring hospitalization for COVID‐19 in this period, included at a 4:1 ratio. Patient, disease, and treatment characteristics were extracted from electronic medical records and a questionnaire. Potential risk factors were analyzed using unconditional logistic regression, corrected for confounders and multiple testing. Eighty‐one cases and 396 controls were included. General risk factors of older age and obesity apply to patients with IRD as well (odds ratio (OR) for age ≥ 75 3.5, 95% confidence interval (CI) 1.9–6.3, OR for body mass index ≥ 40 4.5, 95% CI 1.5–14). No significantly increased ORs for COVID‐19 hospitalization were found for any antirheumatic agent or IRD. A protective effect was found for use of methotrexate (OR 0.53, 95% CI 0.31–0.92). In conclusion, similar to the general population, elderly and obese patients with IRD have a higher risk for hospitalization for COVID‐19. We did not identify a specific antirheumatic agent or IRD to increase the risk of COVID‐19 hospitalization in patients with IRD, except for a possible protective effect of methotrexate.Keywords
Funding Information
- Gilead Sciences
This publication has 20 references indexed in Scilit:
- Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?Clinical Drug Investigation, 2020
- Silencing of immune activation with methotrexate in patients with COVID-19Journal of the Neurological Sciences, 2020
- Associations between hypovitaminosis D and COVID-19: a narrative reviewAging Clinical and Experimental Research, 2020
- Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registryAnnals of the Rheumatic Diseases, 2020
- Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritisAnnals of the Rheumatic Diseases, 2020
- Prevalence and pattern of comorbidities in chronic rheumatic and musculoskeletal diseases: the COMORD studyScientific Reports, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysisThe Lancet, 2015
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateAnnals of the Rheumatic Diseases, 2014
- The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatmentRheumatology, 2012